Cancer stem cell-directed therapies: Recent data from the laboratory and clinic

Molecular Therapy

Volumn 17, Issue 2, 2009, Pages 219-230

  Park, Christopher Y ^a   Tseng, Diane ^a,b   Weissman, Irving L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABCB5 ANTIBODY; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CD19 ANTIBODY; CD22 ANTIBODY; CD44 ANTIBODY; CYTARABINE; DAUNORUBICIN; DIMETHYLAMINOPARTHENOLIDE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 4 ANTIBODY; LAPATINIB; MONOCLONAL ANTIBODY; PARTHENOLIDE; RAPAMYCIN; RITUXIMAB; TDZD 8; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENICITY; CELL RENEWAL; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; GLIOBLASTOMA; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PROGNOSIS; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; BIOLOGICAL MODEL;

HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 63649119820     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.254     Document Type: Review

References (130)

1. Vogelstein, B and Kinzler, KW (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799.
2. Hanahan, D and Weinberg, RA (2000). The hallmarks of cancer. Cell 100: 57-70.
3. Fearon, ER and Vogelstein, B (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
4. Jones, RJ, Matsui, WH and Smith, BD (2004). Cancer stem cells: Are we missing the target? J Natl Cancer Inst 96: 583-585.
5. Huntly, BJ and Gilliland, DG (2005). Cancer biology: Summing up cancer stem cells. Nature 435: 1169-1170.
6. Graham, SM, Jørgensen, HG, Allan, E, Pearson, C, Alcorn, MJ, Richmond, L et al. (2002). Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
7. Hammond, SM (2006). MicroRNAs as oncogenes. Curr Opin Genet Dev 16: 4-9.
8. Holtz, MS, Slovak, ML, Zhang, F, Sawyers, CL, Forman, SJ and Bhatia, R (2002). Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99: 3792-3800.
9. Price, JE and Tarin, D (1989). Low incidence of tumourigenicity in agarose colonies from spontaneous murine mammary tumours. Differentiation 41: 202-207.
10. Gioanni, J, Farges, MF, Duplay, H, Hery, M, Zanghellini, E, Schneider, M et al. (1988). In vitro clonogenicity in relation to kinetic and clinicopathological features of breast cancer. Bull Cancer 75: 285-290.
11. Sabbath, KD, Ball, ED, Larcom, P, Davis, RB and Griffin, JD (1985). Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 75: 746-753.
12. Griffin, JD and Lowenberg, B (1986). Clonogenic cells in acute myeloblastic leukemia. Blood 68: 1185-1195.
13. Bruce, WR and Van Der Gaag, H (1963). A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199: 79-80.
14. Park, CH, Bergsagel, DE and McCulloch, EA (1971). Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46 411-422.
15. Southam, C and Brunschwig, A (1961). Quantitative studies of autotransplantation of human cancer. Cancer 14: 481-463.
16. Lagos-Quintana, M, Rauhut, R, Lendeckel, W and Tuschl, T (2001). Identification of novel genes coding for small expressed RNAs. Science 294: 853-858.
17. Dalerba, P, Cho, RW and Clarke, MF (2007). Cancer stem cells: Models and concepts. Annu Rev Med 58: 267-284.
18. Wicha, MS, Liu, S and Dontu, G (2006). Cancer stem cells: An old idea - a paradigm shift. Cancer Res 66: 1883-1890; discussion 1895-1886.
19. Bonnet, D and Dick, JE (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
20. Lapidot, T, Sirard, C, Vormoor, J, Murdoch, B, Hoang, T, Caceres-Cortes, J et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
21. Baum, CM, Weissman, IL, Tsukamoto, AS, Buckle, AM and Peault, B (1992). Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89: 2804-2808.
22. + hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 6: 262-271.
23. Miyamoto, T, Weissman, IL and Akashi, K (2000). AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 97: 7521-7526.
24. Majeti, R, Park, CY and Weissman, IL (2007). Identification of a Hierarchy of Multipotent Hematopoietic Progenitors in Human Cord Blood. Cell Stem Cell 1: 635-645.
25. Kondo, M, Wagers, AJ, Manz, MG, Prohaska, SS, Scherer, DC, Beilhack, GF et al. (2003). Biology of hematopoietic stem cells and progenitors: Implications for clinical application. Annu Rev Immunol 21: 759-806.
26. Reya, T, Morrison, SJ, Clarke, MF and Weissman, IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
27. Clarke, MF, Dick, JE, Dirks, PB, Eaves, CJ, Jamieson, CH, Jones, DL et al. (2006). Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
28. Weissman, I (2005). Stem cell research: Paths to cancer therapies and regenerative medicine. JAMA 294: 1359-1366.
29. Jamieson, CH, Ailles, LE, Dylla, SJ, Muijtjens, M, Jones, C, Zehnder, JL et al. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
30. Al-Hajj, M, Wicha, MS, Benito-Hernandez, A, Morrison, SJ and Clarke, MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
31. Stingl, J, Eaves, CJ, Kuusk, U and Emerman, JT (1998). Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation 63: 201-213.
32. Lee, Y, Kim, M, Han, J, Yeom, KH, Lee, S, Baek, SH et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23 4051-4060.
33. Gudjonsson, T, Villadsen, R, Nielsen, HL, Ronnov-Jessen, L, Bissell, MJ and Petersen, OW (2002). Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 16: 693-706.
34. Liu, R, Wang, X, Chen, GY, Dalerba, P, Gurney, A, Hoey, T et al. (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226.
35. Dalerba, P, Dylla, SJ, Park, IK, Liu, R, Wang, X, Cho, RW et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163.
36. Li, C, Heidt, DG, Dalerba, P, Burant, CF, Zhang, L, Adsay, V et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
37. Collins, AT, Berry, PA, Hyde, C, Stower, MJ and Maitland, NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
38. Prince, ME, Sivanandan, R, Kaczorowski, A, Wolf, GT, Kaplan, MJ, Dalerba, P et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978.
39. + cancer stem cells in human liver cancer. Cancer Cell 13: 153-166.
40. Richardson, GD, Robson, CN, Lang, SH, Neal, DE, Maitland, NJ and Collins, AT (2004). CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539-3545.
41. + precursors from the ventricular zone of human fetal brain by magnetic affinity cell sorting. Biotechnol Lett 26: 1131-1136.
42. Mizrak, D, Brittan, M and Alison, MR (2008). CD133: Molecule of the moment. J Pathol 214: 3-9.
43. Singh, SK, Clarke, ID, Terasaki, M, Bonn, VE, Hawkins, C, Squire, J et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
44. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
45. Hemmati, HD, Nakano, I, Lazareff, JA, Masterman-Smith, M, Geschwind, DH, Bronner-Fraser, M et al. (2003). Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183.
46. Castor, A, Nilsson, L, Astrand-Grundström, I, Buitenhuis, M, Ramirez, C, Anderson, K et al. (2005). Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11: 630-637.
47. O'Brien, CA, Pollett, A, Gallinger, S and Dick, JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
48. Ricci-Vitiani, L, Lombardi, DG, Pilozzi, E, Biffoni, M, Todaro, M, Peschle, C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
49. Todaro, M, Alea, MP, Di Stefano, AB, Cammareri, P, Vermeulen, L, Iovino, F et al. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402.
50. Hermann, PC, Huber, SL, Herrler, T, Aicher, A, Ellwart, JW, Guba, M et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
51. Eramo, A, Lotti, F, Sette, G, Pilozzi, E, Biffoni, M, Di Virgilio, A et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514.
52. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
53. Schatton, T, Murphy, GF, Frank, NY, Yamaura, K, Waaga-Gasser, AM, Gasser, M et al. (2008). Identification of cells initiating human melanomas. Nature 451: 345-349.
54. Hess, DA, Meyerrose, TE, Wirthlin, L, Craft, TP, Herrbrich, PE, Creer, MH et al. (2004). Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104: 1648-1655.
55. Hess, DA, Wirthlin, L, Craft, TP, Herrbrich, PE, Hohm, SA, Lahey, R et al. (2006). Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107: 2162-2169.
56. Armstrong, L, Stojkovic, M, Dimmick, I, Ahmad, S, Stojkovic, P, Hole, N et al. (2004). Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22: 1142-1151.
57. Cheung, AM, Wan, TS, Leung, JC, Chan, LY, Huang, H, Kwong, YL et al. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21: 1423-1430.
58. Pearce, DJ, Taussig, D, Simpson, C, Allen, K, Rohatiner, AZ, Lister, TA, Bonnet, D et al. (2005). Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23: 752-760.
59. Ginestier, C, Hur, MH, Charafe-Jauffret, E, Monville, F, Dutcher, J, Brown, M, Jacquemier, J et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
60. Dylla, SJ, Beviglia, L, Park, IK, Chartier, C, Raval, J, Ngan, L et al. (2008). Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3: E2428.
61. Cox, CV, Evely, RS, Oakhill, A, Pamphilon, DH, Goulden, NJ and Blair, A (2004). Characterization of acute lymphoblastic leukemia progenitor cells. Blood 104: 2919-2925.
62. Cox, CV, Martin, HM, Kearns, PR, Virgo, P, Evely, RS and Blair, A (2007). Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 109: 674-682.
63. Eisterer, W, Jiang, X, Christ, O, Glimm, H, Lee, KH, Pang, E et al. (2005). Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19: 435-441.
64. Matsui, W, Huff, CA, Wang, Q, Malehorn, MT, Barber, J, Tanhehco, Y et al. (2004). Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
65. Matsui, W, Wang, Q, Barber, JP, Brennan, S, Smith, BD, Borrello, I et al. (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190-197.
66. Hill, RP (2006). Identifying cancer stem cells in solid tumors: Case not proven. Cancer Res 66: 1891-1895; discussion 1890.
67. Kelly, PN, Dakic, A, Adams, JM, Nutt, SL and Strasser, A (2007). Tumor growth need not be driven by rare cancer stem cells. Science 317: 337.
68. Kennedy, JA, Barabe, F, Poeppl, AG, Wang, JC and Dick, JE (2007). Comment on "Tumor growth need not be driven by rare cancer stem cells". Science 318: 1722; author reply 1722.
69. Ishikawa, F, Yoshida, S, Saito, Y, Hijikata, A, Kitamura, H, Tanaka, S et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321.
70. Calabrese, C, Poppleton, H, Kocak, M, Hogg, TL, Fuller, C, Hamner, B et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
71. Taussig, DC, Miraki-Moud, F, Anjos-Afonso, F, Pearce, DJ, Allen, K, Ridler, C et al. (2008). Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
72. Vermeulen, L, Todaro, M, de Sousa Mello, F, Sprick, MR, Kemper, K, Perez Alea, M et al. (2008). Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 105: 13427-13432.
73. Clarke, MF and Fuller, M (2006). Stem cells and cancer: Two faces of eve. Cell 124: 1111-1115.
74. Liotta, LA and Kohn, EC (2001). The microenvironment of the tumour-host interface. Nature 411: 375-379.
75. Ailles, LE and Weissman, IL (2007). Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466.
76. Dean, M, Fojo, T and Bates, S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
77. Jordan, CT and Guzman, ML (2004). Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23: 7178-7187.
78. Mimeault, M, Hauke, R, Mehta, PP and Batra, SK (2007). Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11: 981-1011.
79. Tang, C, Ang, BT and Pervaiz, S (2007). Cancer stem cell: Target for anti-cancer therapy. Faseb J 21: 3777-3785.
80. Ward, RJ and Dirks, PB (2007). Cancer Stem Cells: At the Headwaters of Tumor Development. Annu Rev Pathol 2: 175-189.
81. - progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403-4411.
82. Guan, Y, Gerhard, B and Hogge, DE (2003). Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101: 3142-3149.
83. Guzman, ML, Neering, SJ, Upchurch, D, Grimes, B, Howard, DS, Rizzieri, DA et al. (2001). Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 2301-2307.
84. Holyoake, T, Jiang, X, Eaves, C and Eaves, A (1999). Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064.
85. Eramo, A, Ricci-Vitiani, L, Zeuner, A, Pallini, R, Lotti, F, Sette, G et al. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241.
86. + cancer stem cells in glioblastoma. Mol Cancer 5: 67.
87. Li, X, Lewis, MT, Huang, J, Gutierrez, C, Osborne, CK, Wu, MF et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
88. Bao, S, Wu, Q, McLendon, RE, Hao, Y, Shi, Q, Hjelmeland, AB et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
89. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
90. Lagasse, E (2008). Cancer stem cells with genetic instability: The best vehicle with the best engine for cancer. Gene Ther 15: 136-142.
91. Lederberg, J and Lederberg, EM (1952). Replica plating and indirect selection of bacterial mutants. J Bacteriol 63: 399-406.
92. Luria, SE and Delbruck, M (1943). Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics 28: 491-511.
93. Frei, E 3rd, Karon, M, Levin, RH, Freireich, EJ, Taylor, RJ, Hananian, J et al. (1965). The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642-656.
94. Huff, CA, Matsui, WH, Douglas Smith, B and Jones, RJ (2006). Strategies to eliminate cancer stem cells: Clinical implications. Eur J Cancer 42: 1293-1297.
95. Coiffier, B, Lepage, E, Briere, J, Herbrecht, R, Tilly, H, Bouabdallah, R, Morel, P, Van Den Neste, E et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
96. Michor, F (2007). Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells 25: 1114-1118.
97. Michor, F, Hughes, TP, Iwasa, Y, Branford, S, Shah, NP, Sawyers, CL et al. (2005). Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
98. Sleijfer, S, Gratama, JW, Sieuwerts, AM, Kraan, J, Martens, JW and Foekens, JA (2007). Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 43: 2645-2650.
99. Riethdorf, S, Wikman, H and Pantel, K (2008). Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123: 1991-2006.
100. Pantel, K, Brakenhoff, RH and Brandt, B (2008). Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8: 329-340.
101. Lobo, NA, Shimono, Y, Qian, D and Clarke, MF (2007). The Biology of Cancer Stem Cells. Annu Rev Cell Dev Biol 23: 675-699.
102. Huntly, BJ and Gilliland, DG (2005). Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5: 311-321.
103. Krause, DS and Van Etten, RA (2007). Right on target: Eradicating leukemic stem cells. Trends Mol Med 13: 470-481.
104. Guzman, ML, Swiderski, CF, Howard, DS, Grimes, BA, Rossi, RM, Szilvassy, SJ et al. (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99: 16220-16225.
105. Guzman, ML, Li, X, Corbett, CA, Rossi, RM, Bushnell, T, Liesveld, JL et al. (2007). Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 110: 4436-4444.
106. Guzman, ML, Rossi, RM, Neelakantan, S, Li, X, Corbett, CA, Hassane, DC et al. (2007). An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427-4435.
107. Dahia, PL, Aguiar, RC, Alberta, J, Kum, JB, Caron, S, Sill, H et al. (1999). PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanism haematological malignancies. Hum Mol Genet 8: 185-193.
108. Yilmaz, OH, Valdez, R, Theisen, BK, Guo, W, Ferguson, DO, Wu, H et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
109. Zhang, J, Grindley, JC, Yin, T, Jayasinghe, S, He, XC, Ross, JT et al. (2006). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518-522.
110. Piccirillo, SG, Reynolds, BA, Zanetti, N, Lamorte, G, Binda, E, Broggi, G et al. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765.
111. Konopleva, M, Contractor, R, Tsao, T, Samudio, I, Ruvolo, PP, Kitada, S et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.
112. Peacock, CD, Wang, Q, Gesell, GS, Corcoran-Schwartz, IM, Jones, E, Kim, J et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 104: 4048-4053.
113. Fan, X, Matsui, W, Khaki, L, Stearns, D, Chun, J, Li, YM et al. (2006). Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66: 7445-7452.
114. Golay, J, Lazzari, M, Facchinetti, V, Bernasconi, S, Borleri, G, Barbui, T et al. (2001). CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98: 3383-3389.
115. Lopez-Guillermo, A and Mercadal, S (2007). The clinical use of antibodies in haematological malignancies. Ann Oncol 18 (Suppl 9): Ix51-ix57.
116. Buelow, R and van Schooten, W (2006). The future of antibody therapy. Ernst Schering Found Symp Proc 4: 83-106.
117. Taussig, DC, Pearce, DJ, Simpson, C, Rohatiner, AZ, Lister, TA, Kelly, G et al. (2005). Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.
118. + AML stem cells. Eur J Clin Invest 37: 73-82.
119. Kyoda, K, Nakamura, S, Hattori, N, Takeshima, M, Nakamura, K, Kaya, H et al. (1998). Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. Am J Hematol 57: 265-266.
120. Selleri, C, Notaro, R, Catalano, L, Fontana, R, Del Vecchio, L and Rotoli, B (1992). Prognostic irrelevance of CD34 in acute myeloid leukaemia. Br J Haematol 82: 479-481.
121. Bradstock, K, Matthews, J, Benson, E, Page, F and Bishop, J (1994). Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 84: 1220-1225.
122. - leukemic progenitors. Leukemia 13 1513-1518.
123. Haferlach, T, Schoch, C, Löffler, H, Gassmann, W, Kern, W, Schnittger, S et al. (2003). Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: Results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 21: 256-265.
124. van Rhenen, A, Feller, N, Kelder, A, Westra, AH, Rombouts, E, Zweegman, S et al. (2005). High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11: 6520-6527.
125. Pearce, DJ, Taussig, D, Zibara, K, Smith, LL, Ridler, CM, Preudhomme, C et al. (2006). AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 107: 1166-1173.
126. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11: 1154-1159.
127. Ben-Porath, I, Thomson, MW, Carey, VJ, Ge, R, Bell, GW, Regev, A et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
128. Zeppernick, F, Ahmadi, R, Campos, B, Dictus, C, Helmke, BM, Becker, N et al. (2008). Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129.
129. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
130. Jin, L, Hope, KJ, Zhai, Q, Smadja-Joffe, F and Dick, JE (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.